ARTICLE | Company News
Corimmun, J&J deal
July 2, 2012 7:00 AM UTC
Johnson & Johnson's Janssen-Cilag GmbH unit acquired CorImmun for an upfront payment and milestones. CorImmun's COR-1, a cyclic peptide targeting autoantibodies directed against adrenergic receptor ...